<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975932</url>
  </required_header>
  <id_info>
    <org_study_id>TACE-ICIs-RWS</org_study_id>
    <nct_id>NCT04975932</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study</brief_title>
  <acronym>CHANCE001</acronym>
  <official_title>Efficacy and Safety of Transarterial Chemoembolization in Combination With Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: a Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of transarterial&#xD;
      chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients&#xD;
      with hepatocellular carcinoma (HCC) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transarterial chemoembolization (TACE) can induce immunogenic cell death and tumor-specific&#xD;
      immune response which results in the release of tumor antigens and transform &quot;cold&quot; tumors&#xD;
      with lacking immune effector cells into &quot;hot&quot; tumors with immune effector cells infiltration.&#xD;
      This provides a theoretical basis for TACE combined with immune checkpoint inhibitors (ICIs)&#xD;
      in hepatocellular carcinoma (HCC) patients. The purpose of this study is to evaluate the&#xD;
      safety and efficacy of TACE in combination with ICIs in patients with HCC. This real-world&#xD;
      study also explores the optimal combined treatment and outcome of HCC patients for providing&#xD;
      further information for clinical practice and trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>up to approximately 1 years</time_frame>
    <description>The PFS is defined as the time from the initiation of any combination treatment to progression according to mRECIST or death from any cause. When pseudoprogression is suspected by investigator, tumor response will be re-assessed per iRECIST to confirm (also applicable for secondary endpoint of efficacy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to approximately 2 years</time_frame>
    <description>The OS is defined as the time from the initiation of any combination treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression(TTP)</measure>
    <time_frame>up to approximately 1 years</time_frame>
    <description>The TTP is defined as the time from the initiation of any combination treatment to progression according to mRECIST. When pseudoprogression is suspected by investigator, tumor response will be re-assessed per iRECIST to confirm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>6-8 week after TACE</time_frame>
    <description>The ORR is defined as the proportion of patients with a documented complete response or partial response per mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>6-8 week after TACE</time_frame>
    <description>The DCR is defined as the proportion of patients with a documented complete response, partial response, or stable disease according to mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event(AE)</measure>
    <time_frame>baseline to end of study (approximately 2 years)</time_frame>
    <description>Number and degree of the AEs according to CTCAE version 5.0.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">542</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Study group: TACE+ICIs</arm_group_label>
    <description>TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: TACE</arm_group_label>
    <description>TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TACE+ICIs</intervention_name>
    <description>TACE plus ICIs ( with or without molecular targeted therapies)</description>
    <arm_group_label>Study group: TACE+ICIs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE without combination of ICIs ( with or without molecular targeted therapies)</description>
    <arm_group_label>Control group: TACE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HCC who are candidates for TACE combined with ICIs therapies under real-world&#xD;
        practice conditions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosed with HCC by radiology, histology, or cytology;&#xD;
&#xD;
          2. patients who underwent TACE combined with ICIs therapies ( with or without molecular&#xD;
             targeted therapies) were included in the study group. For patients in the study group,&#xD;
             ICIs therapies were received before the TACE or within 2 months after TACE and at&#xD;
             least one cycle of immunotherapy has been received;&#xD;
&#xD;
          3. during the same period, patients who underwent TACE without the combination of ICIs&#xD;
             therapies ( with or without molecular targeted therapies) were included into the&#xD;
             control group;&#xD;
&#xD;
          4. patients who underwent TACE combined with ICIs therapies and molecular targeted&#xD;
             therapies, molecular targeted therapies must be performed simultaneously with TACE or&#xD;
             immunotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. exceeding the time interval of the combination therapy defined above;&#xD;
&#xD;
          2. missing follow-up data;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao-Jun Teng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongda hospital, Southeast university, Nanjing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gao-Jun Teng, MD</last_name>
    <phone>+86-02583272121</phone>
    <email>gjteng@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hai-Dong Zhu, MD</last_name>
    <phone>+86-02583272121</phone>
    <email>zhuhaidong9509@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gao-Jun Teng</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai-Dong Zhu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9. Review.</citation>
    <PMID>32430997</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3. Review.</citation>
    <PMID>33479224</PMID>
  </reference>
  <reference>
    <citation>Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, Coukos G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol. 2020 Sep;21(9):e419-e430. doi: 10.1016/S1470-2045(20)30234-5. Review.</citation>
    <PMID>32888471</PMID>
  </reference>
  <reference>
    <citation>Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci. 2021 Jan 15;7:609322. doi: 10.3389/fmolb.2020.609322. eCollection 2020.</citation>
    <PMID>33521054</PMID>
  </reference>
  <reference>
    <citation>Leppelmann KS, Mooradian MJ, Ganguli S, Uppot RN, Yamada K, Irani Z, Wehrenberg-Klee EP, Zubiri L, Reynolds KL, Arellano RS, Hirsch JA, Sullivan RJ, Fintelmann FJ. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J Vasc Interv Radiol. 2021 Feb;32(2):187-195. doi: 10.1016/j.jvir.2020.09.014. Epub 2021 Jan 19.</citation>
    <PMID>33353814</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Gao-jun Teng</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>transarterial chemoembolization</keyword>
  <keyword>immune checkpoint iInhibitors</keyword>
  <keyword>real-world study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorotrianisene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

